English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 93 Help

Selected(0)Clear Items/Page:    Sort:
Engineering hyaluronic acid-based nanoassemblies for monoclonal antibody delivery – design, characterization, and biological insights Journal article
López-Estévez, Ana M., Zhang, Y., Medel, María, Arriaga, Iker, Sanjurjo, Lucía, Huck-Iriart, Cristian, Abrescia, Nicola G.A., Vicent, María J., Ouyang, Defang, Torres, Dolores, Alonso, María José. Engineering hyaluronic acid-based nanoassemblies for monoclonal antibody delivery – design, characterization, and biological insights[J]. Nano Research, 2024, 17(10), 9111-9125.
Authors:  López-Estévez, Ana M.;  Zhang, Y.;  Medel, María;  Arriaga, Iker;  Sanjurjo, Lucía; et al.
Favorite | TC[WOS]:0 TC[Scopus]:1  IF:9.5/9.0 | Submit date：2024/08/05
Monoclonal Antibody  Nanoparticles  Hyaluronic Acid  Characterization  Particle Size  Computational Modeling  
AntiFormer: graph enhanced large language model for binding affinity prediction Journal article
Wang, Qing, Feng, Yuzhou, Wang, Yanfei, Li, Bo, Wen, Jianguo, Zhou, Xiaobo, Song, Qianqian. AntiFormer: graph enhanced large language model for binding affinity prediction[J]. Briefings in Bioinformatics, 2024, 25(5), bbae403.
Authors:  Wang, Qing;  Feng, Yuzhou;  Wang, Yanfei;  Li, Bo;  Wen, Jianguo; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:6.8/7.9 | Submit date：2024/09/03
Antibody Binding Affinity  Antibody Maturation  Large Language Model  Single-cell Bcr  
Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model Journal article
Chang, Zhen, Gao, Dan, Liao, Liying, Sun, Junqing, Zhang, Gen, Zhang, Xue, Wang, Feiran, Li, Chunrui, Oladejo, Babayemi Olawale, Li, Shihua, Chai, Yan, Hu, Yongfei, Lu, Xuancheng, Xiao, Haixia, Qi, Jianxun, Chen, Zhihai, Gao, Feng, Wu, Yan. Bispecific antibodies targeting two glycoproteins on SFTSV exhibit synergistic neutralization and protection in a mouse model[J]. Proceedings of the National Academy of Sciences of the United States of America, 2024, 121(24), e2400163121.
Authors:  Chang, Zhen;  Gao, Dan;  Liao, Liying;  Sun, Junqing;  Zhang, Gen; et al.
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:9.4/10.8 | Submit date：2024/07/04
Bispecific Antibody  Bunyavirus  Glycoproteins  Sftsv  Structural Basis  
Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells Journal article
Zhou, Guangyu, Fu, Shengyu, Zhang, Yunsen, Li, Shuang, Guo, Ziang, Ouyang, Defang, Ying, Tianlei, Lu, Yinying, Zhao, Qi. Antibody Recognition of Human Epidermal Growth Factor Receptor-2 (HER2) Juxtamembrane Domain Enhances Anti-Tumor Response of Chimeric Antigen Receptor (CAR)-T Cells[J]. Antibodies, 2024, 13(2), 45.
Authors:  Zhou, Guangyu;  Fu, Shengyu;  Zhang, Yunsen;  Li, Shuang;  Guo, Ziang; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:3.0/4.7 | Submit date：2024/08/05
Car-t Cell  Her2  Monoclonal Antibody  Trastuzumab  
Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies Journal article
He, Qingwen, An, Yaling, Zhou, Xuemei, Xie, Haitang, Tao, Lifeng, Li, Dedong, Zheng, Anqi, Li, Linjie, Xu, Zepeng, Yu, Shufan, Wang, Ruyue, Hu, Hua, Liu, Kefang, Wang, Qihui, Dai, Lianpan, Xu, Kun, Gao, George F.. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies[J]. Med, 2024, 5(5), 401-413.e4.
Authors:  He, Qingwen;  An, Yaling;  Zhou, Xuemei;  Xie, Haitang;  Tao, Lifeng; et al.
Favorite | TC[WOS]:3 TC[Scopus]:4 | Submit date：2024/05/16
Ba.2.86  Eg.5  Eg.5.1  Immune Evasion  Jn.1  Neutralizing Antibody  Rbd-dimer  Sars-cov-2  Translation To Humans  Zf2001 Vaccine  Zf2202-a  
Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2 Journal article
Rao, Xia, Zhao, Runchu, Tong, Zhou, Guo, Shuxin, Peng, Weiyu, Liu, Kefang, Li, Shihua, Wu, Lili, Tong, Jianyu, Chai, Yan, Han, Pu, Wang, Feiran, Jia, Peng, Li, Zhaohui, Zhao, Xin, Li, Dedong, Zhang, Rong, Zhang, Xue, Zou, Weiwei, Li, Weiwei, Wang, Qihui, Gao, George Fu, Wu, Yan, Dai, Lianpan, Gao, Feng. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2[J]. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120(52), e2314193120.
Authors:  Rao, Xia;  Zhao, Runchu;  Tong, Zhou;  Guo, Shuxin;  Peng, Weiyu; et al.
Favorite | TC[WOS]:8 TC[Scopus]:9  IF:9.4/10.8 | Submit date：2024/01/02
Cryptic Epitope  Neutralizing Antibody  Omicron Ba.4/ba.5/bq.1.1/xbb Subvariant  Rbd-8  Sars-cov-2  
Editorial: Therapeutic antibody domains against cancer Other
2023-08-28
Authors:  Zhao, Qi;  Li, Wei;  Dimitrov, Dimiter S.
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date：2023/08/30
Antibody Domain  Bispecific Antibody  Cancer  Immune Checkpoint  Monoclonal Antibody  Phage Display  
Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects Journal article
Bai, Ganggang, Sun, Chance, Guo, Ziang, Wang, Yangjing, Zeng, Xincheng, Su, Yuhong, Zhao, Qi, Ma, Buyong. Accelerating antibody discovery and design with artificial intelligence: Recent advances and prospects[J]. Seminars in Cancer Biology, 2023, 95, 13-24.
Authors:  Bai, Ganggang;  Sun, Chance;  Guo, Ziang;  Wang, Yangjing;  Zeng, Xincheng; et al.
Adobe PDF | Favorite | TC[WOS]:10 TC[Scopus]:13  IF:12.1/13.2 | Submit date：2023/08/25
Antibody  Artificial Intelligence  Antibody Design  Machine Learning  Therapeutic  
Editorial: New mechanistic insights into cancer precision medicine Other
2023-02-16
Authors:  Kwok,Hang Fai
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date：2023/08/03
Immunotherapy  Targeted Therapy  Therapeutic Antibody  Chemotherapy  Novel Bioactive Molecule  Biomarker  Drug Resistance  
A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis Journal article
Li, Junnan, Chen, Pengchen, Wu, Qiushuang, Guo, Libin, Leong, Ka Weng, Chan, Kin Iong, Kwok, Hang Fai. A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis[J]. Cellular and Molecular Life Sciences, 2022, 79(12), 614.
Authors:  Li, Junnan;  Chen, Pengchen;  Wu, Qiushuang;  Guo, Libin;  Leong, Ka Weng; et al.
Favorite | TC[WOS]:7 TC[Scopus]:6  IF:6.2/7.7 | Submit date：2023/01/30
Antibody Therapy  Cell Death  Drug Target  Precision Oncology  Small Molecule